[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342625-105":59,"doc-detail-342625-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-survey-of-carboplatin-desensitization-therapy-in-japan-a-multicenter-retrospective-study","A survey of carboplatin desensitization therapy in Japan - A multicenter retrospective study","","Introduction and objective: Hypersensitivity reactions (HSRs) to chemotherapy are serious adverse events that can occur with any antitumor drug. This multicenter retrospective study evaluated the safety and efficacy of carboplatin desensitization therapy in Japan and sought to establish a practical approach for managing carboplatin HSRs. Methods: Patients with gynecological cancers receiving carboplatin desensitization therapy from 2016 to 2020 were registered via an online case report form. Results: Among 136 patients, common onset symptoms were erythema and pruritus; desensitization was completed in 75% with breakthrough HSRs in 25%. No deaths occurred. Conclusion: High success was observed; erythema and pruritus were key HSRs to consider.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-survey-of-carboplatin-desensitization-therapy-in-japan-a-multicenter-retrospective-study/342625/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-survey-of-carboplatin-desensitization-therapy-in-japan-a-multicenter-retrospective-study/342625.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient population and time period were included in the study?","Question",{"text":112,"@type":113},"Patients with gynecological cancers who underwent carboplatin desensitization therapy between 2016 and 2020 at participating centers were included and registered through an online case report form.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How often was carboplatin desensitization successfully completed, and what were breakthrough HSR rates?",{"text":117,"@type":113},"Desensitization treatment was completed in 75% of cases, while breakthrough HSRs occurred in 25% (34/136) during the desensitization period.",{"name":119,"@type":110,"acceptedAnswer":120},"Which symptoms were most common at the onset of hypersensitivity reactions?",{"text":121,"@type":113},"Erythema was the most common symptom at HSR onset (68.4%), followed by itching/pruritus (52.9%); decreased oxygen saturation occurred in 31.6%.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342625,1790817642,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","DOI: 10. 1002/cam4 .6968  \nRESEAR CH ARTICLE  \nA survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study  \nHiroaki Komatsu1  | Koji Matsumoto2  | Mitsunori Morita2 |  \nTakayuki Nagasawa3 | Hiroshi Nishio4 | Jiro Suzuki5 | Shin Nishio6  |  \nHisanori Kobara7 | Mayu Yunokawa8 | Kazuya Ariyoshi9 | Takashi Hirayama10 | Hideki Tokunaga11 | Masayo Ukita12 | Kaori Yoriki13 | Mayuyo Mori-Uchino14 | Akiko Furusawa15 | Shinichi Togami16 | Hiroko Nakamura17 | Mitsuya Ishikawa18 | Toyomi Satoh19  \nCorrespondence  \nHiroaki Komatsu, Department of Obsterics and Gynecology, Tottori University School of Medicine, 36-1, Nishicho, Yonago, Tottori 683-8504, Japan. [Email:](Email: komatsu.h.med@gmail.com)[ komatsu.h.med@gmail.com](Email: komatsu.h.med@gmail.com)  \nKoji Matsumoto, Department of Medical Oncology, Hyogo Cancer Center, 13-70, Kitaoji-cho, Akashi, Hyogo 673-8558, Japan. [Email:](Email: kojmatsu2@hyogo-cc.jp)[ kojmatsu2@hyogo-cc.jp](Email: kojmatsu2@hyogo-cc.jp)  \nAbstract  \nIntroduction: Hypersensitivity reactions (HSRs) to chemotherapy are serious adverse events associated with cancer drug therapy and can occur with any antitumor drug. This study investigated the safety and efficacy of carboplatin desensitization therapy in Japan and established a method for treating carboplatin HSRs. Methods: Patients diagnosed with gynecological (ovarian, endometrial, or cervical) cancers who underwent carboplatin desensitization therapy between 2016 and 2020 at the Gynecologic Cancer Study Group of Japan Clinical Oncology Group were included. The carboplatin desensitization therapy at each institution and the implementation cases were registered in an online case report form. Results: This retrospective study enrolled 136 patients (ovarian, 108; endometrial, 17; and cervical cancer, 11). Pre-existing allergies were present in 37 (27.2%) patients, and 32 (23.5%) patients exhibited prodromal symptoms during treatment before HSR onset. Erythema was the most common symptom at HSR onset, affecting 93 (68.4%) patients, followed by itching in 72 (52.9%) patients and decreased oxygen saturation in 43 (31.6%) patients. Loss of consciousness occurred in three (2.2%) patients. The most common timing of HSR onset was during the first recurrence treatment (47%) . The mean total carboplatin dose until HSR onset was 7331 (2620–18,282) mg, and the mean number of doses was 14 (4–63) . Desensitization treatment was completed in 75% of cases, and breakthrough HSRs occurred in 25%(34/136) . No deaths occurred in the study cohort. The risk factors for HSRs were not identified.  \nConclusion: Although carboplatin desensitization therapy has high success rates in Japan, erythema and pruritus are important HSRs to consider.  \n\n| For Affiliation refer page on 7 |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. |\n\nCancer Medicine. 2024;13:e6968 .  \n[https://doi.org/10.1002/cam4.6968](https://doi.org/10.1002/cam4.6968)  \n[wileyonlinelibrary.com/journal/cam4](wileyonlinelibrary.com/journal/cam4)  \n1 of 9  \n1 | INTRODUCTION  \nKEYWORDS  \ncarboplatin, desensitization, erythema, hypersensitivity reaction, pruritus  \nduring the desensitization treatment period as breakthrough HSRs.  \nThe platinum and taxane combination regimen is the primary treatment method for both initial and recurrent cases of gynecologic cancers.1–7 Carboplatin, in particular, was introduced in 1989 as a treatment for ovarian cancer and has become a popular choice mainly because its therapeutic effect is comparable to that ofcisplatin and it has fewer adverse events. However, hypersensitivity reactions (HSRs) have been reported in patients receiving multiple cycles of chemotherapy with carboplatin.8 The frequency of HSRs varies among different","cbCaitZf4DMgZ70n","https://ap.wps.com/l/cbCaitZf4DMgZ70n","pdf",570104,"English","# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What patient population and time period were included in the study?\",\"answer\":\"Patients with gynecological cancers who underwent carboplatin desensitization therapy between 2016 and 2020 at participating centers were included and registered through an online case report form.\"},{\"question\":\"How often was carboplatin desensitization successfully completed, and what were breakthrough HSR rates?\",\"answer\":\"Desensitization treatment was completed in 75% of cases, while breakthrough HSRs occurred in 25% (34/136) during the desensitization period.\"},{\"question\":\"Which symptoms were most common at the onset of hypersensitivity reactions?\",\"answer\":\"Erythema was the most common symptom at HSR onset (68.4%), followed by itching/pruritus (52.9%); decreased oxygen saturation occurred in 31.6%.\"}]","A survey of carboplatin desensitization therapy in Japan - A multicenter retrospective study | PDF",1790047436,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92306aba507818287a7e8f5d8f0357e7.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8aa913e10430f454f28ce614eebdc047.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4bbbe1c053b3b26db48cbc0ff1fa6cd.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6f9b60646259d99b7cf5b778bdabc0e.webp",980,1287]